<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
    <channel>
    <title>PMLiVE RSS Feed: The Editors blog RSS</title>
 <link>http://www.pmlive.com</link>
        <description>PMLiVE RSS Feed: The Editors blog RSS</description>
        <language>en-gb</language>
<image>
<url>http://www.pmlive.com/__data/assets/thumbnail/0003/70842/feed-icon-28x28.png</url>
    <title>PMLiVE RSS Feed: The Editors blog RSS</title>
 <link>http://www.pmlive.com</link>
</image>
        <item>
  <title>Jeux sans frontières</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2017/jeux_sans_frontieres_1214909</link>
  <description><![CDATA[<p>From regulations to customs, 2018 has some big questions to answer</p>]]></description>
  <pubDate>Fri, 22 Dec 2017 11:47:00 +0000</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2017/jeux_sans_frontieres_1214909</guid>
</item> <item>
  <title>Can NICE deliver on its funding promises?</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2017/march/can_nice_deliver_on_its_funding_promises_1188730</link>
  <description><![CDATA[<p>The Institute is now half-way thorugh its Cancer Drugs Fund reappraisals</p>]]></description>
  <pubDate>Fri, 10 Mar 2017 11:47:33 +0000</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2017/march/can_nice_deliver_on_its_funding_promises_1188730</guid>
</item> <item>
  <title>Brexit: Bad for health, science and pharma</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2016/june/brexit_bad_for_health,_science_and_pharma_1041019</link>
  <description><![CDATA[<p>Health care voices join the life sciences sector in warning of the negative impact of leaving the EU</p>]]></description>
  <pubDate>Wed, 15 Jun 2016 12:13:09 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2016/june/brexit_bad_for_health,_science_and_pharma_1041019</guid>
</item> <item>
  <title>Finalists revealed for Communiqué Awards 2016</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2016/june/finalists_revealed_for_communique_awards_2016_1037312</link>
  <description><![CDATA[









Forty-three agencies in the running for one of
the prestigious prizes

]]></description>
  <pubDate>Thu, 09 Jun 2016 10:24:39 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2016/june/finalists_revealed_for_communique_awards_2016_1037312</guid>
</item> <item>
  <title>GSK and Novartis asset swap: a tale of two companies</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2023/march/gsk_and_novartis_asset_swap_a_tale_of_two_companies_677593</link>
  <description><![CDATA[Firms complete multi-billion dollar exchange ofoncology, vaccines and consumer health interests]]></description>
  <pubDate>Fri, 13 Mar 2015 12:37:37 +0000</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2023/march/gsk_and_novartis_asset_swap_a_tale_of_two_companies_677593</guid>
</item> <item>
  <title>2014: a year to build pharma's reputation</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2022/july/2014_a_year_to_build_pharmas_reputation_581727</link>
  <description><![CDATA[ Recent megamerger prospects have led to a backlash in the mainstream media ]]></description>
  <pubDate>Wed, 02 Jul 2014 00:03:52 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2022/july/2014_a_year_to_build_pharmas_reputation_581727</guid>
</item> <item>
  <title>Burden of proof</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2022/june/burden_of_proof_576416</link>
  <description><![CDATA[Breakthroughs in Alzheimer's are sorely needed, but there's still lots of work to do on AD04 ]]></description>
  <pubDate>Fri, 06 Jun 2014 17:27:54 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2022/june/burden_of_proof_576416</guid>
</item> <item>
  <title>A sharper focus</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2022/may/a_sharper_focus_568856</link>
  <description><![CDATA[The enthusiasm for massive M&amp;A deals is set to redraw industry boundaries ]]></description>
  <pubDate>Fri, 16 May 2014 00:15:39 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2022/may/a_sharper_focus_568856</guid>
</item> <item>
  <title>Open season?</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2022/february/open_season_543667</link>
  <description><![CDATA[The EMA's decision to post minutes of CHMP meetings is another step forward for industry transparency

]]></description>
  <pubDate>Mon, 17 Feb 2014 00:01:24 +0000</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2022/february/open_season_543667</guid>
</item> <item>
  <title>Resistance's irresistible need</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2022/january/resistances_irresistible_need_533313</link>
  <description><![CDATA[Industry's anti-infective efforts step up a gear ]]></description>
  <pubDate>Tue, 14 Jan 2014 00:00:45 +0000</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2022/january/resistances_irresistible_need_533313</guid>
</item> <item>
  <title>Moving parts</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2013/december/moving_parts_527807</link>
  <description><![CDATA[We end 2013 with reports suggesting that pharma is still 'weathering the storm'

]]></description>
  <pubDate>Tue, 17 Dec 2013 00:00:49 +0000</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2013/december/moving_parts_527807</guid>
</item> <item>
  <title>Singing a simple song?</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2013/october/singing_a_simple_song_511864</link>
  <description><![CDATA[As the EMA consultation on clinical trial data closes, what next in the transparency debate?]]></description>
  <pubDate>Tue, 22 Oct 2013 00:16:12 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2013/october/singing_a_simple_song_511864</guid>
</item> <item>
  <title>Pitfalls and profits in China</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2013/september/pitfalls_and_profits_503242</link>
  <description><![CDATA[What does the corruption investigation in China mean for pharma?]]></description>
  <pubDate>Tue, 17 Sep 2013 00:00:02 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2013/september/pitfalls_and_profits_503242</guid>
</item> <item>
  <title>Resistance is futile?</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2013/august/resistance_is_futile_494840</link>
  <description><![CDATA[Debating the inevitability of transparency]]></description>
  <pubDate>Thu, 08 Aug 2013 00:00:01 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2013/august/resistance_is_futile_494840</guid>
</item> <item>
  <title>The hunted now hunt: biotechs become buyers</title>
  <link>http://www.pmlive.com/blogs/the_editors/archive/2013/june/the_hunted_now_hunt_484257</link>
  <description><![CDATA[As investor interest in biotech grows, larger companies are competing with pharma to acquire smaller firms]]></description>
  <pubDate>Wed, 19 Jun 2013 15:53:32 +0100</pubDate>
  <guid>http://www.pmlive.com/blogs/the_editors/archive/2013/june/the_hunted_now_hunt_484257</guid>
</item>     </channel>
</rss>